KRAS and non-small cell lung carcinoma: Using cell cultures and mouse models, Dong Hoon Shin at the National Cancer Center in Goyang-si, South Korea, and co-workers demonstrated that KRAS mutations confer resistance to chemotherapy in NSCLC cells.